CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Truist Securiti upped their Q2 2021 earnings estimates for CRISPR Therapeutics in a report released on Wednesday, April 28th. Truist Securiti analyst J. Lee now expects that the company will post earnings per share of $9.28 for the quarter, up from their previous estimate of ($1.42). Truist Securiti also issued estimates for CRISPR Therapeutics’ Q3 2021 earnings at ($1.44) EPS, Q4 2021 earnings at ($1.45) EPS, FY2021 earnings at $5.49 EPS and FY2022 earnings at ($5.86) EPS.
CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, April 26th. The company reported ($1.51) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.47) by ($0.04). CRISPR Therapeutics had a negative return on equity of 20.72% and a negative net margin of 273.10%.
Shares of NASDAQ CRSP opened at $115.73 on Monday. The stock has a market capitalization of $8.77 billion, a PE ratio of -35.50 and a beta of 2.37. The business has a fifty day moving average price of $122.88 and a two-hundred day moving average price of $136.77. CRISPR Therapeutics has a fifty-two week low of $50.63 and a fifty-two week high of $220.20.
Institutional investors and hedge funds have recently bought and sold shares of the company. Nikko Asset Management Americas Inc. increased its holdings in CRISPR Therapeutics by 3.8% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,836,823 shares of the company’s stock worth $587,456,000 after buying an additional 139,156 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in CRISPR Therapeutics by 8.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,774,436 shares of the company’s stock valued at $271,684,000 after purchasing an additional 143,504 shares in the last quarter. BlackRock Inc. lifted its holdings in CRISPR Therapeutics by 1.7% in the 4th quarter. BlackRock Inc. now owns 1,173,259 shares of the company’s stock valued at $179,640,000 after purchasing an additional 19,416 shares in the last quarter. Morgan Stanley raised its holdings in shares of CRISPR Therapeutics by 45.3% during the 4th quarter. Morgan Stanley now owns 731,427 shares of the company’s stock worth $111,988,000 after acquiring an additional 227,927 shares during the period. Finally, Norges Bank purchased a new position in shares of CRISPR Therapeutics during the 4th quarter worth $86,215,000. Hedge funds and other institutional investors own 66.43% of the company’s stock.
In other news, Director Bradley J. Phd Bolzon sold 30,374 shares of the company’s stock in a transaction dated Monday, March 22nd. The stock was sold at an average price of $132.37, for a total value of $4,020,606.38. Following the completion of the transaction, the director now owns 57,149 shares of the company’s stock, valued at $7,564,813.13. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 17.10% of the company’s stock.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
Further Reading: Bond
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.